Flamel Technologies S.A. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel's drug delivery platforms. The Company owns and develops drug delivery platforms, including Micropump, LiquiTime, Trigger Lock and Medusa. The Company has two direct operating subsidiaries: Flamel US Holdings, Inc. and Flamel Irish Holdings, Ltd.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Delivery
- Sub-Industry: N/A
- Symbol: NASDAQ:AVDL
- CUSIP: N/A
- Web: www.avadel.com
Capitalization:- Market Cap: $424.93 million
- Outstanding Shares: 41,376,000
Average Prices:- 50 Day Moving Avg: $10.71
- 200 Day Moving Avg: $10.08
- 52 Week Range: $8.75 - $15.45
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 26.33
- P/E Growth: 0.19
Sales & Book Value:- Annual Revenue: $166.54 million
- Price / Sales: 2.55
- Book Value: $1.43 per share
- Price / Book: 7.18
Profitability:- EBIDTA: $58.4 million
- Net Margins: -7.28%
- Return on Equity: 14.49%
- Return on Assets: 2.74%
Debt:- Debt-to-Equity Ratio: 0.01%
- Current Ratio: 2.43%
- Quick Ratio: 2.37%
Misc:- Average Volume: 192,700 shs.
- Beta: 1.41
- Short Ratio: 2.27
Frequently Asked Questions for Flamel Technologies S.A. (NASDAQ:AVDL)
What is Flamel Technologies S.A.'s stock symbol?
Flamel Technologies S.A. trades on the NASDAQ under the ticker symbol "AVDL."
How were Flamel Technologies S.A.'s earnings last quarter?
Flamel Technologies S.A. (NASDAQ:AVDL) issued its quarterly earnings results on Tuesday, May, 9th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.07 by $0.19. The business had revenue of $52.50 million for the quarter, compared to analyst estimates of $46.01 million. Flamel Technologies S.A. had a negative net margin of 7.28% and a positive return on equity of 14.49%. The company's revenue was up 45.0% compared to the same quarter last year. View Flamel Technologies S.A.'s Earnings History.
What guidance has Flamel Technologies S.A. issued on next quarter's earnings?
Flamel Technologies S.A. issued an update on its FY17 earnings guidance on Tuesday, May, 9th. The company provided EPS guidance of $0.30-0.45 for the period, compared to the Thomson Reuters consensus estimate of $0.21. The company issued revenue guidance of $170-185 million, compared to the consensus revenue estimate of $176.97 million.
Where is Flamel Technologies S.A.'s stock going? Where will Flamel Technologies S.A.'s stock price be in 2017?
2 equities research analysts have issued 1 year price objectives for Flamel Technologies S.A.'s shares. Their forecasts range from $16.00 to $16.00. On average, they expect Flamel Technologies S.A.'s share price to reach $16.00 in the next year. View Analyst Ratings for Flamel Technologies S.A..
Who are some of Flamel Technologies S.A.'s key competitors?
Some companies that are related to Flamel Technologies S.A. include Orthofix International N.V. (OFIX), Intersect ENT (XENT), Amphastar Pharmaceuticals (AMPH), Pharmerica Corporation (PMC), AtriCure (ATRC), Reata Pharmaceuticals (RETA), Aclaris Therapeutics (ACRS), Keryx Biopharmaceuticals (KERX), Achaogen (AKAO), Flexion Therapeutics (FLXN), China Cord Blood Corporation (CO), Epizyme (EPZM), Retrophin (RTRX), Arena Pharmaceuticals (ARNA), ZIOPHARM Oncology (ZIOP), La Jolla Pharmaceutical Company (LJPC), TG Therapeutics (TGTX) and PTC Therapeutics (PTCT).
Who owns Flamel Technologies S.A. stock?
Flamel Technologies S.A.'s stock is owned by many different of institutional and retail investors. Top institutional shareholders include US Bancorp DE (0.03%) and Baldwin Brothers Inc. MA (0.02%). Company insiders that own Flamel Technologies S.A. stock include Craig R Stapleton, Francis Fildes, Guillaume Cerutti, Healthcare Master Fun Broadfin, Michael S Anderson, Phillandas T Thompson and Sandra L Hatten. View Institutional Ownership Trends for Flamel Technologies S.A..
How do I buy Flamel Technologies S.A. stock?
Shares of Flamel Technologies S.A. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Flamel Technologies S.A.'s stock price today?
One share of Flamel Technologies S.A. stock can currently be purchased for approximately $10.27.
MarketBeat Community Rating for Flamel Technologies S.A. (NASDAQ AVDL)MarketBeat's community ratings are surveys of what our community members think about Flamel Technologies S.A. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Flamel Technologies S.A. (NASDAQ:AVDL) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $16.00 (55.79% upside) |
Analysts' Ratings History for Flamel Technologies S.A. (NASDAQ:AVDL)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/28/2016 | JMP Securities | Reiterated Rating | Outperform | $16.00 | N/A |  |
| 9/27/2016 | Leerink Swann | Reiterated Rating | Outperform | $16.00 | N/A | |
| 1/21/2016 | Laidlaw | Lower Price Target | Buy | $30.00 -> $25.00 | N/A | |
| 1/11/2016 | Roth Capital | Lower Price Target | Buy | $21.00 -> $17.50 | N/A | |
| 1/4/2016 | SunTrust Banks, Inc. | Reiterated Rating | Buy | | N/A | |
(Data available from 7/24/2015 forward)
Earnings History for Flamel Technologies S.A. (NASDAQ:AVDL)Earnings History by Quarter for Flamel Technologies S.A. (NASDAQ AVDL)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/9/2017 | 3/31/2017 | $0.07 | $0.26 | $46.01 million | $52.50 million | View | Listen | |
| 3/7/2017 | 12/31/2016 | ($0.03) | $0.26 | $34.72 million | $43.09 million | View | Listen | |
| 11/7/2016 | Q316 | ($0.07) | ($0.08) | $30.70 million | $32.10 million | View | Listen | |
| 8/8/2016 | Q216 | $0.06 | ($0.02) | $32.80 million | $38.90 million | View | N/A | |
| 5/9/2016 | Q116 | $0.14 | $0.04 | $34.00 million | $36.20 million | View | N/A | |
| 3/10/2016 | Q415 | $0.09 | $0.32 | $44.69 million | $43.40 million | View | Listen | |
| 11/12/2015 | Q215 | $0.23 | $0.28 | $50.33 million | $47.30 million | View | Listen | |
| 7/30/2015 | Q2 | $0.40 | $0.34 | $62.50 million | $49.80 million | View | Listen | |
| 5/15/2015 | Q115 | $0.18 | $0.34 | $37.37 million | $32.73 million | View | Listen | |
| 3/19/2015 | Q414 | ($0.22) | ($0.12) | $13.10 million | $3.00 million | View | N/A | |
| 10/31/2014 | Q3 14 | ($0.12) | ($0.16) | $12.00 million | $7.00 million | View | N/A | |
| 7/29/2014 | Q214 | ($0.08) | ($0.13) | $9.92 million | $8.10 million | View | N/A | |
| 5/12/2014 | Q1 14 | ($0.15) | ($0.15) | $7.47 million | $9.20 million | View | N/A | |
| 10/31/2013 | Q313 | ($0.20) | ($0.25) | $6.47 million | $5.60 million | View | N/A | |
| 7/29/2013 | Q2 2013 | ($0.27) | ($0.09) | $5.35 million | $5.50 million | View | N/A | |
| 5/7/2013 | Q1 2013 | ($0.33) | ($0.23) | $6.11 million | $5.10 million | View | N/A | |
| 11/5/2012 | Q312 | ($0.19) | ($0.26) | $6.35 million | $5.40 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Flamel Technologies S.A. (NASDAQ:AVDL)2017 EPS Consensus Estimate: $0.21
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | $0.06 | $0.07 | $0.07 |
| Q2 2017 | 3 | $0.06 | $0.08 | $0.07 |
| Q3 2017 | 3 | ($0.03) | $0.07 | $0.03 |
| Q4 2017 | 3 | $0.00 | $0.07 | $0.04 |
(Data provided by Zacks Investment Research)
Dividend History for Flamel Technologies S.A. (NASDAQ:AVDL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Flamel Technologies S.A. (NASDAQ:AVDL)Insider Ownership Percentage: 5.07%
Institutional Ownership Percentage: 70.43%
Insider Trades by Quarter for Flamel Technologies S.A. (NASDAQ:AVDL)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/23/2017 | Healthcare Master Fun Broadfin | Major Shareholder | Sell | 261,000 | $10.68 | $2,787,480.00 | |
| 6/15/2017 | Guillaume Cerutti | Director | Sell | 26,560 | $10.46 | $277,817.60 | |
| 5/22/2017 | Craig R Stapleton | Director | Buy | 31,013 | $9.85 | $305,478.05 | |
| 5/19/2017 | Michael S Anderson | CEO | Buy | 2,500 | $10.00 | $25,000.00 | |
| 11/29/2016 | Craig R Stapleton | Director | Buy | 20,000 | $10.79 | $215,800.00 | |
| 11/21/2016 | Michael S. Anderson | CEO | Buy | 2,000 | $10.64 | $21,280.00 | |
| 9/22/2016 | Francis Fildes | Director | Sell | 15,000 | $13.45 | $201,750.00 | |
| 9/2/2016 | Michael S. Anderson | CEO | Buy | 2,000 | $14.12 | $28,240.00 | |
| 9/1/2016 | Craig R Stapleton | Director | Buy | 10,000 | $13.52 | $135,200.00 | |
| 8/26/2016 | Craig R Stapleton | Director | Buy | 20,000 | $13.76 | $275,200.00 | |
| 8/22/2016 | Michael S. Anderson | CEO | Buy | 5,000 | $14.30 | $71,500.00 | |
| 5/16/2016 | Craig R Stapleton | Director | Buy | 27,228 | $9.21 | $250,769.88 | |
| 5/12/2016 | Michael S Anderson | CEO | Buy | 5,000 | $8.84 | $44,200.00 | |
| 3/22/2016 | Phillandas T Thompson | Insider | Buy | 10,000 | $11.10 | $111,000.00 | |
| 3/18/2016 | Michael S Anderson | CEO | Buy | 5,000 | $11.04 | $55,200.00 | |
| 3/18/2016 | Sandra L Hatten | VP | Buy | 3,000 | $11.01 | $33,030.00 | |
| 3/14/2016 | Craig R Stapleton | Director | Buy | 100,000 | $10.39 | $1,039,000.00 | |
| 3/14/2016 | Michael S Anderson | Insider | Buy | 10,000 | $9.74 | $97,400.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Flamel Technologies S.A. (NASDAQ:AVDL)
Latest Headlines for Flamel Technologies S.A. (NASDAQ:AVDL)
| Source: |
|
| Date | Headline |
|---|
 | Head-To-Head Analysis: Flamel Technologies (AVDL) and Acura Pharmaceuticals (ACUR)
www.americanbankingnews.com - July 23 at 2:12 PM |
| Flamel Technologies S.A. (NASDAQ:AVDL) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - July 21 at 7:16 PM |
 | Avadel Pharmaceuticals to Report Second Quarter 2017 Results
finance.yahoo.com - July 20 at 5:42 PM |
| Comparing Flamel Technologies (AVDL) & Acura Pharmaceuticals (ACUR)
www.americanbankingnews.com - July 19 at 2:34 PM |
| Flamel Technologies (AVDL) & Acura Pharmaceuticals (ACUR) Financial Review
www.americanbankingnews.com - July 19 at 10:44 AM |
| Acura Pharmaceuticals (ACUR) & Flamel Technologies (NASDAQ:AVDL) Financial Survey
www.americanbankingnews.com - July 19 at 12:14 AM |
| Contrasting Flamel Technologies (AVDL) and Acura Pharmaceuticals (ACUR)
www.americanbankingnews.com - July 17 at 10:32 PM |
| Flamel Technologies S.A. (AVDL) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - July 17 at 8:26 PM |
| Critical Comparison: Flamel Technologies (AVDL) versus Acura Pharmaceuticals (ACUR)
www.americanbankingnews.com - July 16 at 8:12 PM |
| Head to Head Analysis: Flamel Technologies (NASDAQ:AVDL) and Acura Pharmaceuticals (ACUR)
www.americanbankingnews.com - July 16 at 10:35 AM |
| Financial Review: Acura Pharmaceuticals (ACUR) vs. Flamel Technologies (AVDL)
www.americanbankingnews.com - July 16 at 7:46 AM |
| Critical Survey: Acura Pharmaceuticals (ACUR) versus Flamel Technologies (NASDAQ:AVDL)
www.americanbankingnews.com - July 13 at 10:23 PM |
| ETFs with exposure to Avadel Pharmaceuticals Plc : July 13, 2017
finance.yahoo.com - July 13 at 4:59 PM |
| Acura Pharmaceuticals (ACUR) versus Flamel Technologies (NASDAQ:AVDL) Financial Review
www.americanbankingnews.com - July 9 at 7:34 AM |
| Contrasting Acura Pharmaceuticals (ACUR) & Flamel Technologies (NASDAQ:AVDL)
www.americanbankingnews.com - July 7 at 12:24 PM |
| Head to Head Analysis: Acura Pharmaceuticals (ACUR) & Flamel Technologies (NASDAQ:AVDL)
www.americanbankingnews.com - July 6 at 2:44 PM |
| Reviewing Acura Pharmaceuticals (ACUR) and Flamel Technologies (NASDAQ:AVDL)
www.americanbankingnews.com - July 5 at 6:36 PM |
| Flamel Technologies S.A. (AVDL) Expected to Announce Quarterly Sales of $44.17 Million
www.americanbankingnews.com - July 5 at 9:39 AM |
| Brokerages Expect Flamel Technologies S.A. (NASDAQ:AVDL) Will Post Earnings of $0.06 Per Share
www.americanbankingnews.com - July 3 at 10:20 PM |
| ETFs with exposure to Avadel Pharmaceuticals Plc : July 3, 2017
finance.yahoo.com - July 3 at 4:01 PM |
| Healthcare Master Fun Broadfin Sells 261,000 Shares of Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Stock
www.americanbankingnews.com - June 26 at 7:16 PM |
| Flamel Technologies S.A. (AVDL) Director Guillaume Cerutti Sells 26,560 Shares
www.americanbankingnews.com - June 19 at 7:35 PM |
| ETFs with exposure to Avadel Pharmaceuticals Plc : June 16, 2017
finance.yahoo.com - June 16 at 4:27 PM |
| Avadel Pharmaceuticals Plc :AVDL-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017
finance.yahoo.com - June 14 at 10:16 AM |
| Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) & Bio-Path Holdings (BPTH) Head to Head Comparison
www.americanbankingnews.com - June 10 at 8:30 PM |
| Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Expected to Announce Quarterly Sales of $44.17 Million
www.americanbankingnews.com - June 9 at 12:38 PM |
| $0.06 Earnings Per Share Expected for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) This Quarter
www.americanbankingnews.com - June 7 at 8:21 PM |
| Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) & Petmed Express (PETS) Head-To-Head Survey
www.americanbankingnews.com - June 5 at 12:47 PM |
| Michael S. Anderson Acquires 2,500 Shares of Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Stock
www.americanbankingnews.com - May 22 at 8:14 PM |
| Insider Buying: Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Director Buys 31,013 Shares of Stock
www.americanbankingnews.com - May 22 at 7:46 PM |
| Avadel Pharmaceuticals Supports the Narcolepsy Network's 5th Annual DREAM BIG Walk
finance.yahoo.com - May 17 at 12:13 PM |
| Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 12 at 7:42 PM |
| SunTrust Banks Weighs in on Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share's Q2 2017 Earnings (AVDL)
www.americanbankingnews.com - May 12 at 10:40 AM |
| Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Expected to Announce Earnings of $0.05 Per Share
www.americanbankingnews.com - May 11 at 10:10 PM |
| Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Lifted to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - May 9 at 10:28 PM |
| Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Updates FY17 Earnings Guidance
www.americanbankingnews.com - May 9 at 2:24 PM |
| Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 9 at 1:38 PM |
| Investor Network: Avadel Pharmaceuticals plc to Host Earnings Call
finance.yahoo.com - May 9 at 9:04 AM |
| Avadel Pharmaceuticals Reports First Quarter 2017 Results
finance.yahoo.com - May 9 at 9:04 AM |
| Avadel posts 1Q profit
finance.yahoo.com - May 9 at 9:04 AM |
| ETFs with exposure to Avadel Pharmaceuticals Plc : May 3, 2017
finance.yahoo.com - May 3 at 3:48 PM |
| Avadel Pharmaceuticals Plc :AVDL-US: Earnings Analysis: Q4, 2016 By the Numbers : May 2, 2017
finance.yahoo.com - May 2 at 3:47 PM |
| $0.06 EPS Expected for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL) This Quarter
www.americanbankingnews.com - April 21 at 8:31 AM |
| Avadel Pharmaceuticals to Report First Quarter 2017 Results
finance.yahoo.com - April 18 at 11:01 AM |
| SunTrust Banks Weighs in on Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share's FY2018 Earnings (AVDL)
www.americanbankingnews.com - April 3 at 12:52 PM |
| AVADEL PHARMACEUTICALS PLC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Financial Statement
biz.yahoo.com - March 31 at 8:53 PM |
| 4:04 pm Avadel Pharmaceuticals to reduce its headcount in France by approximately 50 people in 'an effort to align the Company's cost structure with its ongoing and future planned projects'
finance.yahoo.com - March 30 at 9:13 PM |
| Avadel Pharmaceuticals Announces Planned Reduction of French Workforce
finance.yahoo.com - March 30 at 4:10 PM |
| AVADEL PHARMACEUTICALS PLC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 28 at 8:46 PM |
| AVADEL PHARMACEUTICALS PLC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - March 17 at 4:22 PM |
Flamel Technologies S.A. (AVDL) Chart for Monday, July, 24, 2017
